Diovan to reduce the mortality by 33% in patients with cardiac faiure

In the recently conducted large trials 'Val-HeFT (valsartan Heart Failure Trial)' to evaluate the efficacy of angiotensin II inhibitor 'valsartan' in 5,010 patients (302 centers in 16 countries) with cardiac failure receiving the conventional medication including beta-blocker, diurectic, digoxin and ACE inhibitor, valsartan reduced the mortality and morbidity by 33.1% and 44%, respectively, in ...